Effects of sugammadex doses up to 32mg/kg alone or in combination with rocuronium or vecuronium on QTC prolongation: A thorough QTC study

Clinical Drug Investigation

Volumn 30, Issue 9, 2010, Pages 599-611

  De Kam, Pieter Jan ^a   Van Kuijk, Jacqueline ^a   Prohn, Marita ^b   Thomsen, Torben ^c   Peeters, Pierre ^a  

^a MSD   (Netherlands)

^b Pharmacokinetics Pharmacodynamics and Pharmacometrics   (Netherlands)

^c CRS Clinical Research Services GmbH   (Germany)

Author keywords

arrhythmias; pharmacodynamics; pharmacokinetics; QT interval prolongation; research and development; rocuronium bromide; sugammadex; vecuronium bromide

Indexed keywords

MOXIFLOXACIN; PLACEBO; ROCURONIUM; SUGAMMADEX; VECURONIUM; ANDROSTANE DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; HETEROCYCLIC COMPOUND; NEUROMUSCULAR BLOCKING AGENT; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD SAMPLING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ELECTROCARDIOGRAM; FEMALE; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PAROSMIA; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SMELLING DISORDER; TELEMETRY; ADOLESCENT; BIOLOGICAL MODEL; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANDROSTANOLS; ARRHYTHMIAS, CARDIAC; AZA COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; GAMMA-CYCLODEXTRINS; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROMUSCULAR NONDEPOLARIZING AGENTS; QUINOLINES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VECURONIUM BROMIDE; YOUNG ADULT;

EID: 77954635156     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11537210-000000000-00000     Document Type: Article

References (28)

1. Guidance for industry E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: 2005 [online]. Available from URL: http://www.fda.gov/CbER/gdlns/iche14qtc.htm [Accessed 2008 Jun 11]
2. Suresh D, Carter JA, Whithead JP, et al. Cardiovascular changes at antagonism of atracurium: effects of different doses of premixed neostigmine and glycopyrronium in a ratio of 5 : 1. Anaesthesia 1991 Oct; 46 (10): 877-880
3. Caldwell JE. Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth Analg 1995 Jun; 80 (6): 1168-1174
4. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 Jul-Aug; 3 (4): 335-348
5. Adam JM, Bennett DJ, BomA, et al.Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002 Apr 25; 45 (9): 1806-1816
6. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002 Jan 18; 41 (2): 266-270
7. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006 Jan; 96 (1): 36-43
8. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006 Apr; 104 (4): 667-674
9. Groudine SB, Soto R, Lien C, et al. A randomized, dosefinding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007 Mar; 104 (13): 555-562
10. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology 2007 May; 106 (5): 935-943
11. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium-or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007 Feb; 106 (2): 283-288
12. Vanacker BF, Vermeyen KM, Struys MMRF, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007 Mar; 104 (3): 563-568
13. Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol 2001 Sept; 67 (9): 637-640
14. Yildirim H, Adanir T, Atay A. The effects of sevoflurane, isoflurane and desflurane on QT interval of the ECG. Eur J Anaesthesiol 2004 Jul; 21 (7): 566-570
15. Cammu G, de Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008 Mar; 100 (3): 373-379
16. Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. London: Chapman and Hall, 2003
17. Shah A, Haijan G. A maximum likelihood approach for estimating the QT correction factor using mixed effects model. Stat Med 2003 Jun; 22 (11): 1901-1909
18. Beal SL, Sheiner LB, Boeckmann AJ, editors. NONMEM users guides. Ellicott City (MD): Icon Development Solutions, 1989-2006
19. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2006 Mar; 81 (3): 377-385
20. Hulhoven R, Rosillon D, Bridson WE, et al. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo-and active-controlled, four-way crossover study. Clin Ther 2008 Feb; 30 (2): 260-270
21. Peeters PAM, van den Heuvel M, van Heumen E, et al. Evaluating the safety and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects. Clin Drug Investig. In press
22. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005 Oct; 103 (4): 695-703
23. de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007 Aug; 107 (2): 239-244
24. Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine glycopyrrolate and edrophonium-atropine. Anesth Analg 2007 Mar; 104 (3): 569-574
25. de Kam PJ, van Kuijk J, Smeets J, et al. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. In: The Annual Meeting of the American Society of Anesthesiologist; 2007 October 13-17; San Francisco (CA). Anesthesiology 2007; 107: A1580
26. Dahl V, Pendeville E, Hollmann MW, et al. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. In: The Annual Meeting of the American Society of Anesthesiologist; 2007 October 13-17; San Francisco (CA). Anesthesiology 2007; 107: A1581
27. Saarnivaara L, Simola M. Effects of four anticholinesterases- anticholinergic combinations and tracheal extubation on QTc interval of theECG, heart rate and arterial pressure. Acta Anaesthesiol Scand 1998 Apr; 42 (4): 460-463
28. Van Vlymen JM, Parlow JL. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 1997 Jan; 84 (1): 148-154